# Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19

> **NCT04542694** · PHASE3 · COMPLETED · sponsor: **Promomed, LLC** · enrollment: 200 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Favipiravir
- **DRUG:** Standard of care

## Key facts

- **NCT ID:** NCT04542694
- **Lead sponsor:** Promomed, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-21
- **Primary completion:** 2020-08-10
- **Final completion:** 2020-08-20
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2020-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04542694

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04542694, "Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT04542694. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*